Zydus Lifesciences Limited (BSE: 532321, NSE: ZYDUSLIFE) has announced the incorporation of a wholly owned subsidiary, Zydus MedTech (France) SAS, in France. This development marks a key milestone in the company’s strategy to acquire a controlling stake in Amplitude Surgical SA, a French orthopedic firm. The new subsidiary, incorporated on April 10, 2025, will facilitate the acquisition of Amplitude Surgical’s equity shares.
As part of the previously disclosed acquisition plan, Zydus Lifesciences has entered into agreements to purchase 85.6% of Amplitude Surgical’s shares for €6.25 per share, totaling €256.8 million. Following the completion of this block acquisition, Zydus intends to launch a mandatory simplified cash tender offer for the remaining shares at the same price. If the conditions are met, the company plans to proceed with a compulsory acquisition (squeeze-out) and eventually delist Amplitude Surgical from the exchange.
Zydus MedTech (France) SAS, with an authorized share capital of €1,000 and a paid-up share capital of €100, will primarily serve as an investment vehicle for this acquisition. The company’s immediate objective is to acquire the equity shares of Amplitude Surgical. Zydus MedTech Private Limited, a wholly owned subsidiary of Zydus Lifesciences, has already subscribed to 1,000 equity shares of the French entity, contributing €1,000 in total, including a share capital of €100 and an issuance premium of €900.
This move underscores Zydus Lifesciences’ commitment to strengthening its global presence, particularly in the orthopedic sector. Further updates on the acquisition process will be shared as they become available.
